H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 9.6% of adults in Jersey City have diagnosed diabetes — 2.4 points below the U.S. 12% figure. Census population 292,449. New Jersey Medicare wound biologics: Novitas Solutions (JL). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Jersey City clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Jersey City storefront.
Fibrin Matrix Therapy Products in Jersey City, NJ for clinics & physicians. Fibrin matrix therapy supports… Compliance support & pricing — contact Hawk Medical.
If a sales sheet cannot tell you that Jersey City is JL (Novitas Solutions) and that adult diabetes here is 9.6% (PLACES 2023), it is selling units, not a program. That is the fibrin matrix therapy conversation we actually have.
National Fibrin Matrix Therapy Products notes (how the product actually works)New Jersey shares JL with DC, DE, MD, PA. Florida is the only single-state MAC. CDC PLACES (2023, crude) estimates 9.6% of adults in Jersey City have diagnosed diabetes — 2.4 points below the U.S. 12% figure. If you also operate in another contractor’s state, say so on the first call — we map both.
Practices hire us when the fridge is full and the chart is a mess. CDC PLACES (2023, crude) estimates 9.6% of adults in Jersey City have diagnosed diabetes — 2.4 points below the U.S. 12% figure. That is a planning input. The work is still receiving, indication language, and not mixing PRP with CTP codes. That is the fibrin matrix therapy account.
CDC PLACES (2023, crude prevalence) estimates 9.6% of adults — 2.4 points below the U.S. 12% figure. Obesity is 26.2%; arthritis is 14.6%. That is place-level BRFSS modeling, not a clinic census and not a Jersey City trial.
We do not publish a consumer directory of every account. Patients should ask their current specialist whether the practice offers fibrin matrix therapy products and which products they use.
It is the Census city-proper count — useful as scale for a city of 250k–500k. It is not a count of orthopedic groups, wound centers, or competitors. Underwrite the program against your referral sources, not against the skyline.
The allograft is used to perform the same basic function in the recipient as in the donor (FDA 361). Using umbilical or amniotic tissue as a marketed “stem cell cure” for unrelated conditions is outside that lane and is a New Jersey compliance risk.
Bring specialty, monthly wound volume, and whether you bill JL FFS, Advantage, workers’ comp, or cash-pay. We already have PLACES 9.6% diabetes and 14.6% arthritis for Jersey City — tell us how that matches your panel. Book 15 minutes with Joe or use the contact form.
Contact us to learn how Hawk Medical supports practices in Jersey City, NJ.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Jersey City is JL geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Jersey City — 2.4 points below the U.S. 12% figure. Planning input, not an outcomes claim.
New Jersey Part B wound biologics follow this contractor (siblings: DC, DE, MD, PA). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Jersey City. Useful for joint-program math; still needs a diagnosis and privileging.
No Jersey City storefront. Joe Bradley is an active practice owner. fibrin matrix therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.